156 related articles for article (PubMed ID: 38281290)
41. A case of conversion hepatectomy for huge ruptured hepatocellular carcinoma after transarterial embolization and lenvatinib therapy.
Naganuma A; Suzuki Y; Hoshino T; Yasuoka H; Tamura Y; Naruse H; Tanaka H; Hirai K; Sakamoto I; Ogawa T; Hatanaka T; Kakizaki S
Clin J Gastroenterol; 2022 Feb; 15(1):177-184. PubMed ID: 34811701
[TBL] [Abstract][Full Text] [Related]
42. Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence.
Hosoda K; Toshima T; Takahashi J; Yonemura Y; Hisamatsu Y; Hirose K; Masuda T; Motomura Y; Abe T; Ando Y; Dairaku K; Nakano Y; Hashimoto M; Hiraki Y; Soejima Y; Yoshizumi T; Mimori K
Int Cancer Conf J; 2023 Oct; 12(4):274-278. PubMed ID: 37577350
[TBL] [Abstract][Full Text] [Related]
43. Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib.
Honda S; Saito Y; Sawada K; Hasebe T; Nakajima S; Okumura T
Intern Med; 2020 Mar; 59(5):657-662. PubMed ID: 31735795
[TBL] [Abstract][Full Text] [Related]
44. [A Case of Multiple Postoperative Recurrence of Hepatocellular Carcinoma Successfully Treated with Atezolizumab plus Bevacizumab].
Fujii J; Shinke G; Takeda Y; Ohmura Y; Katsura Y; Kinoshita M; Aoyama S; Kihara Y; Katsuyama S; Ikeshima R; Hiraki M; Sugimura K; Masuzawa T; Hata T; Murata K
Gan To Kagaku Ryoho; 2023 Jan; 50(1):96-98. PubMed ID: 36759998
[TBL] [Abstract][Full Text] [Related]
45. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt.
Namba M; Kawaoka T; Aikata H; Kodama K; Uchikawa S; Ohya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Chayama K
Clin J Gastroenterol; 2019 Aug; 12(4):341-346. PubMed ID: 30706429
[TBL] [Abstract][Full Text] [Related]
46. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
[TBL] [Abstract][Full Text] [Related]
47. Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report.
Liu Z; Fu Z; Li G; Lin D
Onco Targets Ther; 2020; 13():10267-10273. PubMed ID: 33116607
[TBL] [Abstract][Full Text] [Related]
48. Liver abscess in advanced hepatocellular carcinoma after atezolizumab plus bevacizumab treatment: A case report.
Uchida K; Ozono Y; Uchiyama N; Hatada H; Nakamura K; Komaki Y; Iwakiri H; Hasuike S; Nagata K; Sato Y; Kawakami H
Medicine (Baltimore); 2022 Sep; 101(35):e30486. PubMed ID: 36107543
[TBL] [Abstract][Full Text] [Related]
49. Conversion surgery for advanced hepatocellular carcinoma after combination treatment of lenvatinib and camrelizumab: a case report.
Chen Z; Chen Z; Fan W; Zou Y; Zhang Y; Shi N; Jin H
World J Surg Oncol; 2023 Jan; 21(1):29. PubMed ID: 36721173
[TBL] [Abstract][Full Text] [Related]
50. Conversion surgery after lenvatinib treatment for multiple lung metastases from hepatocellular carcinoma.
Sano S; Asahi Y; Kamiyama T; Kakisaka T; Orimo T; Nagatsu A; Aiyama T; Kazui K; Shomura H; Ueki S; Sakamoto Y; Shirakawa C; Kamachi H; Sugino H; Mitsuhashi T; Taketomi A
Int Cancer Conf J; 2023 Jan; 12(1):7-13. PubMed ID: 36605836
[TBL] [Abstract][Full Text] [Related]
51. Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.
Furuichi N; Naganuma A; Kaburagi T; Suzuki Y; Hoshino T; Shibusawa N; Horiguchi S; Hatanaka T; Kakizaki S; Uraoka T
Clin J Gastroenterol; 2023 Jun; 16(3):422-431. PubMed ID: 36821067
[TBL] [Abstract][Full Text] [Related]
52. Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma.
Maesaka K; Sakamori R; Yamada R; Doi A; Tahata Y; Miyazaki M; Ohkawa K; Mita E; Iio S; Nozaki Y; Yakushijin T; Imai Y; Kodama T; Hikita H; Tatsumi T; Takehara T
Hepatol Res; 2022 Jul; 52(7):630-640. PubMed ID: 35417606
[TBL] [Abstract][Full Text] [Related]
53. A Case of Multiple Intratumoral Hemorrhage and Rupture of Hepatocellular Carcinoma after Starting Lenvatinib.
Ishihara K
Case Reports Hepatol; 2020; 2020():6659388. PubMed ID: 33381332
[TBL] [Abstract][Full Text] [Related]
54. A Case of Hepatocellular Carcinoma Successfully Resumed Atezolizumab and Bevacizumab After Associated Grade 3 Diarrhea and Grade 2 Colitis: Case Report and Literature Review.
Fuji T; Arai J; Otoyama Y; Nio Y; Sugiura I; Nakajima Y; Kajiwara A; Ichikawa Y; Uozumi S; Shimozuma Y; Uchikoshi M; Sakaki M; Nozawa H; Momo K; Sasaki T; Yoshida H
Onco Targets Ther; 2022; 15():1281-1288. PubMed ID: 36303951
[TBL] [Abstract][Full Text] [Related]
55. Hyperthyroidism due to thyrotropin receptor antibody stimulation of metastatic thyroid carcinoma during lenvatinib treatment: a case report.
Toda S; Kadoya M; Matsui A; Murayama D; Iwasaki H
Ann Palliat Med; 2022 Nov; 11(11):3571-3577. PubMed ID: 35726194
[TBL] [Abstract][Full Text] [Related]
56. Two Cases of Intraabdominal Bleeding Caused by Hepatocellular Carcinoma Rupture Soon after the Initiation of Chemotherapy with Lenvatinib.
Sato A; Imai Y; Uchiya H; Uchida Y; Nakazawa M; Sugawara K; Nakayama N; Mochida S
Intern Med; 2022 Aug; 61(15):2301-2305. PubMed ID: 35283380
[TBL] [Abstract][Full Text] [Related]
57. [A Case of Successful Treatment of Recurrent Peritoneal Dissemination of Hepatocellular Carcinoma with Atezolizumab plus Bevacizumab Combination Therapy].
Katsura Y; Takeda Y; Ohmura Y; Sakamoto T; Shinke G; Katsuyama S; Ikeshima R; Kawai K; Hiraki M; Sugimura K; Masuzawa T; Takeno A; Hata T; Murata K
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2027-2029. PubMed ID: 35045482
[TBL] [Abstract][Full Text] [Related]
58. Lenvatinib activates anti-tumor immunity by suppressing immunoinhibitory infiltrates in the tumor microenvironment of advanced hepatocellular carcinoma.
Yamauchi M; Ono A; Amioka K; Fujii Y; Nakahara H; Teraoka Y; Uchikawa S; Fujino H; Nakahara T; Murakami E; Okamoto W; Miki D; Kawaoka T; Tsuge M; Imamura M; Hayes CN; Ohishi W; Kishi T; Kimura M; Suzuki N; Arihiro K; Aikata H; Chayama K; Oka S
Commun Med (Lond); 2023 Oct; 3(1):152. PubMed ID: 37880538
[TBL] [Abstract][Full Text] [Related]
59. [A case of advanced hepatocellular carcinoma wherein readministration was made possible due to successful transcatheter arterial embolization for intratumoral hemorrhage during Lenvatinib administration].
Hara H; Nakano Y; Arai K; Kaneko Y; Sakaki K; Fukami Y; Ikemiyagi H; Yoshino K; Sakita S
Nihon Shokakibyo Gakkai Zasshi; 2022; 119(5):476-485. PubMed ID: 35545547
[TBL] [Abstract][Full Text] [Related]
60. A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib.
Osuga T; Miyanishi K; Ito R; Tanaka S; Hamaguchi K; Ohnuma H; Murase K; Takada K; Nagayama M; Kimura Y; Sugawara T; Sugita S; Takemasa I; Hasegawa T; Kato J
Case Rep Oncol; 2022; 15(1):318-325. PubMed ID: 35529291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
